

Supporting Information

Simplified Analogs of Immucillin-G Retain Potent Human Purine Nucleoside Phosphorylase Inhibitory Activity

Teresa Semeraro,^a Andrea Lossani,^b Maurizio Botta,^a Chiara Ghiron,^c Reinaldo Alvarez,^b Fabrizio Manetti,^a Claudia Mugnaini,^a Silvia Valesin,^c Federico Focher,^{*,b} Federico Corelli^{*,a}

^aDipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via A. De Gasperi 2, 53100 Siena, Italy

^bIstituto di Genetica Molecolare, CNR, via Abbiategrasso 207, 27100 Pavia, Italy

^cSienaBiotech S.p.a., Via Fiorentina 1, 53100 Siena, Italy

Synthetic Procedures and Analytical Data

Compounds prepared *via* Mannich reaction according to general method A

2-Amino-1,5-dihydro-7-[(2*R*)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]-4*H*-pyrrolo[3,2-d]pyrimidin-4-one (1b). Yield 35%; mp 152-154°C (dec); $[\alpha]^{20}_D +13.3$ (*c* 1.5, MeOH); ¹H NMR (CD₃OD): δ 7.48 (s, 1H), 4.48 (d, *J*= 13.7 Hz, 1H), 4.32 (d, *J*= 13.7 Hz, 1H) 3.69 (m, 4H), 3.38 (m, 1H), 2.02 (m, 4H), 1.92 (s, 6H); IR (nujol) ν_{max} 1674, 1634, 1580, 1525, 1199, 1121 cm⁻¹; MS (electrospray) *m/z*: 264 [M+1]; Anal. (C₁₂H₁₇N₅O₂ - 2 CH₃COOH) C, H, N.

2-Amino-1,5-dihydro-7-[(2*S*)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]-4*H*-pyrrolo[3,2-d]pyrimidin-4-one (1c). Yield 25%; mp >260°C (dec); $[\alpha]^{20}_D -65.5$ (*c* 1, MeOH); ¹H NMR (CD₃OD): δ 7.20 (s, 1H), 3.98 (d, *J*= 13.7 Hz, 1H), 3.67 (d, *J*=

13.7 Hz), 3.41 (m, 2H), 3.32 (s, 3H), 2.90 (m, 2H), 2.44 (m, 1H), 1.72 (m, 4H); IR (nujol) ν_{max} 1681, 1633, 1568, 1199, 1124 cm⁻¹; MS (electrospray) *m/z*: 278 [M+1]; Anal. (C₁₃H₁₉N₅O₂) C, H, N.

2-Amino-1,5-dihydro-7-[(2*S*,4*R*)-2-(hydroxymethyl)-4-hydroxy-1-pyrrolidinyl]methyl]-4*H*-pyrrolo[3,2-d]pyrimidin-4-one(1d). Yield 15%; syrup; $[\alpha]^{20}_{\text{D}} -42.66$ (*c* 0.75, MeOH); ¹H NMR (CD₃OD): δ 7.38 (s, 1H), 4.42 (m, 1H), 4.43 (d, *J*= 13.6 Hz, 1H), 4.27 (d, *J*= 13.6 Hz, 1H), 3.73 (m, 3H), 3.46 (m, 1H), 3.24 (m, 1H), 2.03 (m, 2H); IR (nujol) ν_{max} 1697, 1646, 1525, 1105 cm⁻¹; MS (electrospray) *m/z*: 280 [M+1]; Anal. (C₁₂H₁₇N₅O₃) C, H, N.

2-Amino-1,5-dihydro-7-[[N-[2-(hydroxy)ethyl]-N-methyl]amino]methyl]-4*H*-pyrrolo[3,2-d]pyrimidin-4-one (2a). Yield 33%; mp: 89-90 °C; ¹H NMR (CD₃OD): δ 7.44 (s, 1H), 4.32 (s, 2H), 3.88 (t, *J*= 5.1 Hz, 1H), 3.22 (t, *J*= 5.1 Hz, 2H), 2.79 (s, 3H), 1.92 (s, 6H); IR (nujol) ν_{max} 1683, 1558, 1106 cm⁻¹; MS (electrospray) *m/z*: 238 [M+1]; Anal. (C₁₀H₁₅N₅O₂ - 2 CH₃COOH) C, H, N.

2-Amino-1,5-dihydro-7-[[N-[ethyl]-N-[2-(hydroxy)ethyl]amino]methyl]-4*H*-pyrrolo[3,2-d]pyrimidin-4-one (2b). Yield 10%; syrup; ¹H NMR (CD₃OD): δ 7.24 (s, 1H), 3.92 (s, 2H), 3.74 (t, *J*= 5.9 Hz, 2H), 2.92 (t, *J*= 5.9 Hz, 2H), 2.76 (q, *J*= 6.9 Hz, 2H), 1.92 (s, 6H), 1.22 (t, *J*= 6.9 Hz, 3H) MS (electrospray) *m/z*: 252 [M+1]; Anal.(C₁₁H₁₇N₅O₂ - 2 CH₃COOH) C, H, N

2-Amino-1,5-dihydro-7-[[N,N-bis-[2-(hydroxy)ethyl]amino]methyl]-4*H*-pyrrolo[3,2-d]pyrimidin-4-one (2c). Yield 27%; mp: 140-141 °C; ¹H NMR (CD₃OD): δ 7.36 (s, 1H), 4.27 (s, 2H), 3.85 (t, *J*= 5.2, 4H), 3.13 (t, *J*= 5.2, 4H), 1.92 (s, 6H); MS (electrospray) *m/z*: 268 [M+1]; Anal. (C₁₁H₁₇N₅O₃ - 2 CH₃COOH) C, H, N.

2-Amino-1,5-dihydro-7-[[3-(hydroxymethyl)-1-piperidinyl]methyl]-4H-pyrrolo[3,2-d]pyrimidin-4-one (3). Yield 35%; mp 91-93°C; ^1H NMR (CD_3OD): δ 7.41 (s, 1H), 4.17 (s, 2H), 3.42 (m, 2H), 2.66 (m, 4H), 1.92 (s, 6H), 1.78 (m, 3H), 1.2 (m, 2H); IR (nujol) ν_{max} 1686, 1635, 1560, 1533, 1131, 1039 cm^{-1} ; MS (electrospray) m/z : 278 [M+1]; Anal. ($\text{C}_{13}\text{H}_{19}\text{N}_5\text{O}_2$ - 2 CH_3COOH) C, H, N.

Compounds prepared via reductive amination according to general method B

2-Amino-1,5-dihydro-7-[(2S)-2-(benzyloxycarbonylaminomethyl)-1-pyrrolidinyl]methyl]-4H-pyrrolo[3,2-d]pyrimidin-4-one (7). Yield 38%; ^1H NMR (CD_3OD): δ 7.30 (m, 5H), 7.13 (s, 1H), 5.07 (s, 2H), 3.93 (d, $J = 13.5$ Hz, 1H), 3.52 (d, $J = 13.5$ Hz, 1H), 3.35 (m, 3H), 2.90 (m, 1H), 2.65 (m, 1H), 2.32 (m, 1H), 1.82 (m, 1H), 1.59 (m, 2H); MS (electrospray) m/z : 397 [M+1]; Anal. ($\text{C}_{20}\text{H}_{24}\text{N}_6\text{O}_3$) C, H, N.

Synthesis of (S)-2-(benzyloxycarbonylaminomethyl)pyrrolidine hydrochloride. To a solution of (S)-2-aminomethyl-*N*-*tert*-butoxycarbonylpiperidine (80 mg, 0.4 mmol) in 20% aqueous Na_2CO_3 (2 mL) and MeOH (5 mL) at 0 °C benzyl chloroformate (63 L, 0.44 mmol) was added dropwise; the mixture was stirred at 0 °C for 1 h and then at room temperature for 12 h. The solvent was removed under reduced pressure, water was added and the solution was extracted with CH_2Cl_2 (3 x 5 mL); the combined extracts were washed with brine, dried over Na_2SO_4 and concentrated. The crude product was dissolved in MeOH, 12 N HCl (185 L) was added dropwise and the solution was stirred for 12 h. The reaction mixture was then concentrated under reduced pressure to give the title compound as hydrochloride salt (yield 95%); ^1H NMR (CD_3OD): δ 7.32 (m, 5H); 5.08 (s, 2H); 3.69 (m, 1H); 3.43 (m,

2H); 2.06 (m, 4H); 1.73 (m, 2H); MS (electrospray) *m/z*: 235 [M+1]. Anal. (C₁₃H₁₈N₂O₂ • HCl) C, H, N.

Elemental Analyses

Compd	Formula	Calcd.			Found		
		C, %	H, %	N, %	C, %	H, %	N, %
1a	C ₁₂ H ₁₇ N ₅ O ₂ _2 CH ₃ COOH	50.12	6.57	18.27	50.33	6.49	18.11
1b	C ₁₂ H ₁₇ N ₅ O ₂ _2 CH ₃ COOH	50.12	6.57	18.27	50.40	6.66	18.09
1c	C ₁₃ H ₁₉ N ₅ O ₂	56.30	6.91	25.25	56.51	6.80	25.35
1d	C ₁₂ H ₁₇ N ₅ O ₃	51.60	6.14	25.08	51.45	6.20	51.22
1e	C ₁₂ H ₁₈ N ₆ O	54.95	6.92	32.04	55.14	6.84	32.21
2a	C ₁₀ H ₁₅ N ₅ O ₂ _2 CH ₃ COOH	47.05	6.49	19.60	47.29	6.33	19.47
2b	C ₁₁ H ₁₇ N ₅ O ₂ _2 CH ₃ COOH	48.51	6.78	18.86	48.80	6.62	18.58
2c	C ₁₁ H ₁₇ N ₅ O ₃ _2 CH ₃ COOH	46.51	6.50	18.08	46.83	6.40	17.95

2d	C ₉ H ₁₃ N ₅ O ₂ _2 CH ₃ COOH	45.48	6.17	20.40	45.28	6.30	20.23
3	C ₁₃ H ₁₉ N ₅ O ₂ _2 CH ₃ COOH	51.38	6.86	17.62	51.50	6.74	17.49
6	C ₁₆ H ₂₁ N ₅ O ₄	55.32	6.09	20.16	55.11	6.17	54.92
7	C ₂₀ H ₂₄ N ₆ O ₃	60.59	6.10	21.20	60.71	6.19	21.00
CbzHN— Cyclopentyl—NH ⁺ Cl ⁻	C ₁₃ H ₁₉ ClN ₂ O ₂	57.67	7.07	10.35	57.53	7.15	10.22